1. |
|
|
2. |
- Jost, C., et al.
(författare)
-
Real-Time Gesture Recognition Based On Motion Quality Analysis
- 2015
-
Ingår i: Proceedings of the 2015 7th International Conference on Intelligent Technologies for Interactive Entertainment. - : IEEE. ; , s. 47-56
-
Konferensbidrag (refereegranskat)abstract
- This paper presents a robust and anticipative real-time gesture recognition and its motion quality analysis module. By utilizing a motion capture device, the system recognizes gestures performed by a human, where the recognition process is based on skeleton analysis and motion features computation. Gestures are collected from a single person. Skeleton joints are used to compute features which are stored in a reference database, and Principal Component Analysis (PCA) is computed to select the most important features, useful in discriminating gestures. During real-time recognition, using distance measures, real-time selected features are compared to the reference database to find the most similar gesture. Our evaluation results show that: i) recognition delay is similar to human recognition delay, ii) our module can recognize several gestures performed by different people and is morphology-independent, and iii) recognition rate is high: all gestures are recognized during gesture stroke. Results also show performance limits.
|
|
3. |
- Valleix, Sophie, et al.
(författare)
-
D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile
- 2016
-
Ingår i: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 7
-
Tidskriftsartikel (refereegranskat)abstract
- Apolipoprotein C-III deficiency provides cardiovascular protection, but apolipoprotein C-III is not known to be associated with human amyloidosis. Here we report a form of amyloidosis characterized by renal insufficiency caused by a new apolipoprotein C-III variant, D25V. Despite their uremic state, the D25V-carriers exhibit low triglyceride (TG) and apolipoprotein C-III levels, and low very-low-density lipoprotein (VLDL)/high high-density lipoprotein (HDL) profile. Amyloid fibrils comprise the D25V-variant only, showing that wild-type apolipoprotein C-III does not contribute to amyloid deposition in vivo. The mutation profoundly impacts helical structure stability of D25V-variant, which is remarkably fibrillogenic under physiological conditions in vitro producing typical amyloid fibrils in its lipid-free form. D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection even in the unfavourable context of renal failure, extending the evidence for an important cardiovascular protective role of apolipoprotein C-III deficiency. Thus, fibrate therapy, which reduces hepatic APOC3 transcription, may delay amyloid deposition in affected patients.
|
|